Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ELTX Elicio Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: ELTX
Price (delayed)
$4.96
Market cap
$79.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.25
Enterprise value
$86.37M
Highlights
ELTX's equity has dropped by 199% year-on-year but it is up by 40% since the previous quarter
The quick ratio has decreased by 46% QoQ but it has increased by 16% YoY
The net income has declined by 47% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of ELTX
Market
Valuations
Earnings
Shares outstanding
15.95M
Market cap
$79.13M
Enterprise value
$86.37M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$44.99M
Net income
-$51.9M
EBIT
-$51.44M
EBITDA
-$50.27M
Free cash flow
-$37.15M
Per share
Balance sheet
Liquidity
EPS
-$4.25
EPS diluted
-$4.25
Free cash flow per share
-$3.04
Book value per share
-$1.05
Revenue per share
$0
TBVPS
$2.31
Total assets
$28.18M
Total liabilities
$39.49M
Debt
$26.04M
Equity
-$11.31M
Working capital
$9.17M
Debt to equity
-2.3
Current ratio
1.8
Quick ratio
1.63
Net debt/EBITDA
-0.14
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-194.4%
Return on equity
N/A
Return on invested capital
-272.8%
Return on capital employed
-308.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELTX stock price
How has the Elicio Therapeutics stock price performed over time
Intraday
-3.31%
1 week
0.81%
1 month
-6.68%
1 year
-45.19%
YTD
-2.75%
QTD
-19.48%
Financial performance
How have Elicio Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.99M
Net income
-$51.9M
Gross margin
N/A
Net margin
N/A
The net income has declined by 47% year-on-year and by 11% since the previous quarter
The operating income has declined by 26% year-on-year and by 10% since the previous quarter
Price vs fundamentals
How does ELTX's price correlate with its fundamentals
Growth
What is Elicio Therapeutics's growth rate over time
Valuation
What is Elicio Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Elicio Therapeutics's EPS has increased by 39% YoY but it has decreased by 25% from the previous quarter
ELTX's equity has dropped by 199% year-on-year but it is up by 40% since the previous quarter
Efficiency
How efficient is Elicio Therapeutics business performance
The company's return on assets has shrunk by 90% YoY and by 10% QoQ
ELTX's return on invested capital is up by 9% since the previous quarter and by 5% year-on-year
Dividends
What is ELTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELTX.
Financial health
How did Elicio Therapeutics financials performed over time
The total assets is 29% smaller than the total liabilities
ELTX's total liabilities has soared by 150% YoY but it is down by 31% QoQ
The current ratio has contracted by 47% from the previous quarter but it has grown by 7% YoY
ELTX's equity has dropped by 199% year-on-year but it is up by 40% since the previous quarter
Elicio Therapeutics's debt to equity has plunged by 68% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.